Literature DB >> 34550491

Comprehensive registry of esophageal cancer in Japan, 2014.

Masayuki Watanabe1, Yasushi Toh2, Ryu Ishihara3, Koji Kono4, Hisahiro Matsubara5, Kentaro Murakami5, Kei Muro6, Hodaka Numasaki7, Tsuneo Oyama8, Soji Ozawa9, Hiroshi Saeki10, Koji Tanaka11, Takahiro Tsushima12, Masaki Ueno13, Takashi Uno14, Toshiyuki Yoshio15, Shiyori Usune16, Arata Takahashi16, Hiroaki Miyata16.   

Abstract

BACKGROUND: The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes annually.
METHODS: We analyzed the data of patients who had visited the participating hospitals in 2014. We collected the data with a web-based data collection system using the National Clinical Database. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification 7th edition by the Union of International Cancer Control (UICC) for cancer staging.
RESULTS: A total of 9026 cases were registered from 344 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.9% and 7.1%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.1%, 33.7%, 25.3%, and 59.3%, respectively. Esophagectomy was performed in 5204 cases. Concerning the approach used for esophagectomy, 48.1% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.75%, and the hospital mortality was 2.0%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system, because pStage IV included the patients with supraclavicular lymph-node metastasis (M1 LYM).
CONCLUSION: We hope that this report contributes to improving all aspects of diagnosing and treating esophageal cancer in Japan.
© 2021. The Author(s).

Entities:  

Keywords:  Chemoradiotherapy; Chemotherapy; Endoscopic resection; Esophageal cancer; Esophagectomy; Radiotherapy

Mesh:

Year:  2021        PMID: 34550491      PMCID: PMC8738507          DOI: 10.1007/s10388-021-00879-1

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


Preface 2014

We sincerely appreciate the outstanding contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2014 was published here. Since 2019, the data collection method was changed from an electronic submission to a web-based data collection using the National Clinical Database (NCD). Personal information was replaced with individual management code inside each institute, and the NCD collected only anonymized information. The registry complies with the Act for the Protection of Personal Information. We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2014. According to the subject year, the Japanese Classification of Esophageal Cancer 10th by the Japan Esophageal Society (JES) [1] and the Union of International Cancer Control (UICC) TNM Classification 7th [2] were used for cancer staging. A total of 9026 cases were registered from 344 institutions in Japan. Tumor locations were cervical in 4.8%, upper thoracic in 12.9%, middle thoracic in 46.5%, lower thoracic in 27.2%, and esophagogastric junction in 7.8%. Superficial carcinomas (Tis, T1a, T1b) were 37.2%. As for the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 87.9% and 7.1%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.1%, 33.7%, 25.3%, and 59.3%, respectively. The endoscopic submucosal dissection accounted for 92.6% of endoscopic resection. Esophagectomy was performed in 5204 cases. Concerning the approach used for esophagectomy, 48.1% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.75%, and the hospital mortality was 2.0%. The Kaplan–Meier survival curves diverged according to the N-grade both in the JES and the UICC classifications. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. In contrast, in the UICC system, the survival of cStage IIB was better than those of IB and IIA, while the survival curves were almost identical between cStage IIIc and IV. Also, the survival curve of pStage IIB was better than that of IIA, and the survival of pStage IV was better than that of IIIC. pStage IV in the UICC system included the patients with supraclavicular lymph-node metastasis (M1 LYM), which is probably the reason for the better prognosis of pStage IV than pStage IIIC. We hope that this Comprehensive Registry of Esophageal Cancer in Japan 2014 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan. Age and gender Performed treatment Tumor location E esophageal, G gastric Histologic type of biopsy specimens Depth of tumor invasion, cT (UICC TNM 7th) Lymph-node metastasis, cN (UICC TNM 7th) Distant metastasis, cM (UICC TNM 7th) Clinical Stage (UICC TNM 7th) Details of endoscopic treatment for curative intent EMR endoscopic mucosal resection, PDT photodynamic therapy, YAG yttrium aluminum garnet, MCT microwave coagulation therapy, ESD endoscopic submucosal dissection Complications of EMR/ESD Pathologic depth of tumor invasion of MER/ESD specimens Survival of patients treated with EMR/ESD Survival of patients treated with EM/ESD according to the pathological depth of tumor invasion, pT (JES 10th) Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion Dose of irradiation (non-surgically treated cases) Dose of irradiation (surgically treated cases) Survival of patients treated with chemotherapy and/or radiotherapy Survival of patients treated with definitive chemoradiotherapy according to the clinical stage (UICC TNM 7th) Survival of patients who underwent radiotherapy alone according to the clinical stage (UICC TNM 7th) Treatment modalities of esophagectomy Tumor location Approaches to tumor resection Thoracic includes thoracotomy and thoracoscopic. Abdominal includes laparotomy and laparoscopic Video-assisted surgery Fields of lymph-node dissection according to the location of tumor C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes Reconstruction route Organs used for reconstruction Histological classification Pathological depth of tumor invasion, pT (JES 10th) Pathological grading of lymph-node metastasis, pN (JES 10th) Pathological grading of lymph-node metastasis, pN (UICC TNM 7th) Pathological findings of distant organ metastasis, pM (JES 10th) Residual tumor Survival of patients who underwent esophagectomy Survival of patients who underwent esophagectomy according to the clinical stage (JES 10th) Survival of patients who underwent esophagectomy according to the clinical stage (UICC TNM 7th) Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th) Survival of patients who underwent esophagectomy according to lymph-node metastasis (JES 10th) Survival of patients who underwent esophagectomy according to lymph-node metastasis (UICC TNM 7th) Survival of patients who underwent esophagectomy according to the pathological stage (JES 10th) Survival of patients who underwent esophagectomy according to the pathological stage (UICC TNM 7th) Survival of patients

I. Clinical features of esophageal cancer patients treated in 2014

Institution-registered cases in 2014. (Total 344 institutions)

Patient background

Tables 1, 2, 3, 4, 5, 6, 7, 8.
Table 1

Age and gender

AgeMaleFemaleCases (%)
 ≤ 2920424 (0.3)
30–3922729 (0.3)
40–4917974253 (2.8)
50–599952301225 (13.6)
60–6929084823390 (37.6)
70–7927884323220 (35.7)
80–89685148833 (9.2)
90 ≤ 341852 (0.6)
Total763113959026
Table 2

Performed treatment

TreatmentsCases (%)
Surgery5355 (59.3)
 Esophagectomy5204 (57.7)
 Palliative surgery151 (1.7)
Chemotherapy and/or radiotherapy4835 (53.6)
Endoscopic treatment1529 (16.9)
Table 3

Tumor location

Location of tumorEndoscopic treatmentSurgeryChemotherapy and/orTotal (%)
(%)Esophagectomy (%)Palliative surgery (%)radiotherapy (%)
Cervical43 (2.8)185 (3.6)6 (4.0)305 (6.3)436 (4.8)
Upper thoracic164 (10.7)598 (11.5)36 (23.8)738 (15.3)1160 (12.9)
Middle thoracic838 (54.7)2386 (45.8)66 (43.7)2180 (45.1)4200 (46.5)
Lower thoracic378 (24.7)1528 (29.4)35 (23.2)1296 (26.8)2451 (27.2)
EG68 (4.4)378 (7.3)7 (4.6)214 (4.4)531 (5.9)
E = G24 (1.6)64 (1.2)30 (0.6)94 (1.0)
GE7 (0.5)62 (1.2)40 (0.8)85 (0.9)
Unknown7 (0.5)3 (0.1)1 (0.7)32 (0.7)69 (0.8)
Total1529520415148359026

E esophageal, G gastric

Table 4

Histologic type of biopsy specimens

Histologic typesEndoscopic treatmentSurgeryChemotherapy and/orTotal (%)
(%)Esophagectomy (%)Palliative surgery (%)radiotherapy (%)
Squamous cell carcinoma1314 (85.9)4567 (87.8)143 (94.7)4450 (92.0)7938 (87.9)
 Squamous cell carcinoma993 (64.2)2484 (47.7)93 (61.6)2601 (53.8)4819 (53.4)
 Well differentiated104 (6.8)427 (8.2)12 (7.9)320 (6.6)640 (7.1)
 Moderately differentiated172 (11.2)1234 (23.7)29 (19.2)1098 (22.7)1807 (20.0)
 Poorly differentiated45 (2.9)422 (8.1)9 (6.0)431 (8.9)672 (7.4)
Adenocarcinoma41 (2.7)372 (7.1)3 (2.0)199 (4.1)492 (5.5)
Barrett's carcinoma42 (2.7)96 (1.8)1 (0.7)25 (0.5)144 (1.6)
Adenosquamous carcinoma1 (0.1)10 (0.2)7 (0.1)18 (0.2)
Mucoepidermoid carcinoma2 (0.0)1 (0.0)3 (0.0)
Basaloid carcinoma4 (0.3)32 (0.6)19 (0.4)41 (0.5)
Neuroendocrine tumor1 (0.0)1 (0.0)
Neuroendocrine carcinoma1 (0.1)16 (0.3)34 (0.7)41 (0.5)
Undifferentiated carcinoma1 (0.1)4 (0.1)2 (0.0)5 (0.3)
Malignant melanoma18 (0.3)9 (0.2)24 (0.3)
Carcinosarcoma1 (0.1)22 (0.4)12 (0.2)28 (0.3)
GIST7 (0.1)2 (0.0)8 (0.1)
Adenoid cystic carcinoma1 (0.0)1 (0.0)
Nonepithelial tumors2 (0.1)3 (0.1)3 (0.1)6 (0.1)
Other epithelial tumors36 (2.4)8 (0.2)9 (0.2)58 (0.6)
Other tumors26 (1.7)15 (0.3)5 (0.1)47 (0.5)
Unknown60 (3.9)31 (0.6)4 (2.6)57 (2.1)171 (1.9)
Total1529520415148359026
Table 5

Depth of tumor invasion, cT (UICC TNM 7th)

Clinical TEndoscopic treatmentSurgeryChemotherapy and/orTotal (%)
(%)Esophagectomy (%)Palliative surgery (%)radiotherapy (%)
cTX28 (1.8)17 (0.3)4 (2.6)57 (1.2)144 (1.6)
cT017 (1.1)7 (0.1)3 (0.1)30 (0.3)
cT1a1173 (76.7)240 (4.6)112 (2.3)1469 (16.3)
cT1b205 (13.4)1409 (27.1)2 (1.3)644 (13.3)1858 (20.6)
cT29 (0.6)867 (16.7)5 (3.3)667 (13.8)1086 (12.0)
cT346 (3.0)2310 (44.4)62 (41.1)2367 (49.0)3250 (36.0)
cT4a10 (0.7)164 (3.2)13 (8.6)317 (6.6)404 (4.5)
cT4b41 (2.7)190 (3.7)65 (43.0)668 (13.8)785 (8.7)
Total1529520415148359026
Table 6

Lymph-node metastasis, cN (UICC TNM 7th)

Clinical NEndoscopic treatmentSurgeryChemotherapy and/orTotal (%)
(%)Esophagectomy (%)Palliative surgery (%)radiotherapy (%)
cN01426 (93.3)2390 (45.9)20 (13.2)1310 (27.1)4399 (48.7)
cN150 (3.3)1825 (35.1)60 (39.7)1914 (39.6)2627 (29.1)
cN233 (2.2)867 (16.7)56 (37.1)1257 (26.0)1567 (17.4)
cN320 (1.3)122 (2.3)15 (9.9)354 (7.3)433 (4.8)
Total1529520415148359026
Table 7

Distant metastasis, cM (UICC TNM 7th)

Clinical MEndoscopic treatmentSurgeryChemotherapy and/orTotal (%)
(%)Esophagectomy (%)Palliative surgery (%)radiotherapy (%)
cM01494 (97.7)5036 (96.8)108 (71.5)4210 (85.2)8148 (90.3)
cM135 (2.3)168 (3.2)43 (28.5)715 (14.8)878 (9.7)
Total1529520415148359026
Table 8

Clinical Stage (UICC TNM 7th)

Clinical stageEndoscopic treatmentSurgeryChemotherapy and/orTotal (%)
(%)Esophagectomy (%)Palliative surgery (%)radiotherapy (%)
Stage IA1363 (89.1)1307 (25.1)2 (1.3)471 (9.7)2899 (32.1)
Stage IB5 (0.3)458 (8.8)2 (1.3)282 (5.8)558 (6.2)
Stage IIA10 (0.7)531 (10.2)6 (4.0)400 (8.3)649 (7.2)
Stage IIB15 (1.0)577 (11.1)1 (0.7)449 (9.3)680 (7.5)
Stage IIIA14 (0.9)1195 (23.0)21 (13.9)1078 (22.3)1499 (16.6)
Stage IIIB8 (0.5)560 (10.8)16 (10.6)567 (11.7)733 (8.1)
Stage IIIC35 (2.3)385 (7.4)57 (37.7)839 (17.4)997 (11.0)
Stage IV35 (2.3)168 (3.2)43 (28.5)715 (14.8)878 (9.7)
Unknown44 (2.9)23 (0.4)3 (2.0)34 (0.7)133 (1.5)
Total1529520415148359026

I. Results of endoscopically treated patients in 2014

Tables 9, 10, 11, and Figs. 1, 2, 3.
Table 9

Details of endoscopic treatment for curative intent

Treatment detailsCases (%)
EMR104 (7.1)
EMR + YAG laser1 (0.1)
EMR + MCT/RFA
ESD1265 (86.0)
ESD + EMR80 (5.4)
ESD + PDT
ESD + YAG laser2 (0.1)
PDT3 (0.2)
YAG laser16 (1.1)
Total1471

EMR endoscopic mucosal resection, PDT photodynamic therapy, YAG yttrium aluminum garnet, MCT microwave coagulation therapy, ESD endoscopic submucosal dissection

Table 10

Complications of EMR/ESD

Complications of EMR/ESDCases (%)
None1384 (95.8)
Perforation12 (0.8)
Bleeding3 (0.2)
Mediastinitis5 (0.3)
Stenosis41 (2.8)
Others
Unknown
Total1445
Table 11

Pathologic depth of tumor invasion of MER/ESD specimens

Pathological depth of tumor invasion (pT)Cases (%)
pTX17 (1.2)
pT068 (0.5)
pT1a1127 (82.8)
pT1b238 (15.0)
pT2
pT32 (0.1)
Total1452
Fig. 1

Survival of patients treated with EMR/ESD

Fig. 2

Survival of patients treated with EM/ESD according to the pathological depth of tumor invasion, pT (JES 10th)

Fig. 3

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

II. Results in patients treated with chemotherapy and/or radiotherapy in 2014

Tables 12, 13 and Figs. 4, 5, 6.
Table 12

Dose of irradiation (non-surgically treated cases)

Dose of irradiationDefinitivePalliative (%)Recurrence (%)Others (%)Total (%)
(Gy)Radiation alone (%)With chemotherapy (%)
-292 (1.2)16 (1.7)26 (8.4)2 (6.3)3 (37.5)49 (3.3)
30–393 (1.8)17 (1.8)53 (17.1)5 (15.6)78 (5.6)
40–495 (3.0)34 (3.5)56 (18.1)4 (12.5)2 (25.0)101 (6.8)
50–5926 (15.8)246 (25.5)77 (24.8)8 (25.0)1 (12.5)359 (24.2)
60–69124 (75.2)620 (64.4)90 (29.0)11 (34.4)2 (25.0)849 (57.3)
70-4 (2.4)28 (2.9)5 (1.6)2 (.3)39 (2.6)
Unknown1 (0.6)2 (0.2)3 (1.0)6 (0.4)
Total1659633103281481
Median (min–max)60.0 (10.0–70.0)60.0 (2.0–92.0)50.0 (2.0–90.0)50.4 (8.0–70.0)60.0 (50.0–63.4)60.0 (2.0–92.0)
Table 13

Dose of irradiation (surgically treated cases)

Dose ofPreoperativePostoperative
irradiation (Gy)irradiation (%)irradiation (%)
-2912 (3.7)
30–3955 (16.9)3 (5.0)
40–49199 (61.0)9 (15.0)
50–5940 (12.3)20 (33.3)
60–6916 (4.9)24 (40.0)
70-1 (0.3)3 (5.0)
Unknown3 (0.9)1 (1.7)
Total32660
Median (min—max)40.0 (1.8- 70.0)54.0 (30.0 – 97.5)
Fig. 4

Survival of patients treated with chemotherapy and/or radiotherapy

Fig. 5

Survival of patients treated with definitive chemoradiotherapy according to the clinical stage (UICC TNM 7th)

Fig. 6

Survival of patients who underwent radiotherapy alone according to the clinical stage (UICC TNM 7th)

III. Results in patients who underwent esophagectomy in 2014

Tables 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, and Figs. 7, 8, 9, 10, 11, 12, 13, 14, 15
Table 14

Treatment modalities of esophagectomy

Treatment modalitiesCases (%)
Esophagectomy alone2307 (44.3)
Esophagectomy + postoperative chemotherapy387 (7.4)
Esophagectomy + postoperative chemoradiotherapy109 (2.1)
Esophagectomy + postoperative radiotherapy39 (0.7)
Preoperative chemotherapy + Esophagectomy1784 (34.3)
Preoperative chemoradiotherapy + Esophagectomy335 (6.4)
Definitive radiotherapy + Esophagectomy6 (0.1)
Definitive chemoradiotherapy + Esophagectomy124 (2.4)
Others113 (2.2)
Total5204
Table 15

Tumor location

LocationsCases (%)
Cervical209 (3.8)
Upper thoracic655 (12.0)
Middle thoracic2448 (44.9)
Lower thoracic1570 (28.8)
EG380 (7.0)
E = G98 (1.8)
GE80 (1.5)
Unknown11 (0.2)
Total5451
Table 16

Approaches to tumor resection

ApproachesCases (%)
Cervical176 (3.4)
Right thoracic4492 (86.3)
Left thoracic54 (1.0)
Left thoracoabdominal82 (1.6)
Abdominal187 (3.6)
Transhiatal lower esophagectomy133 (2.6)
Transhiatal thoracic esophagectomy64 (1.2)
Sternotomy6 (0.1)
Others7 (0.1)
Unknown3 (0.1)
Total5204

Thoracic includes thoracotomy and thoracoscopic. Abdominal includes laparotomy and laparoscopic

Table 17

Video-assisted surgery

Video-assisted surgeryCases (%)
None2330 (44.6)
Thoracoscopy1206 (23.2)
Thoracoscopy + laparoscopy1281 (24.6)
Thoracoscopy + laparoscopy + mediastinoscopy9 (0.2)
Thoracoscopy + laparoscopy + other
Thoracoscopy + mediastinoscopy1 (0.0)
Thoracoscopy + other4 (0.1)
Laparoscopy265 (5.1)
Laparoscopy + mediastinoscopy41 (0.8)
Laparoscopy + mediastinoscopy + other1 (0.0)
Mediastinoscopy49 (0.9)
Laparoscopy + other1 (0.0)
Others15 (0.3)
Unknown1 (0.0)
Total5204
Table 18

Fields of lymph-node dissection according to the location of tumor

Field of lymphadenectomyCervicalUpper thoracicMiddle thoracicLower thoracicAbdominalE = GGEUnknownTotal
None8 (4.2)15 (2.5)46 (1.9)26 (1.7)4 (1.1)1 (1.1)4 (6.0)104 (2.0)
C47 (24.5)11 (1.8)33 (1.4)14 (0.9)105 (2.0)
C + UM21 (10.9)1 (0.2)2 (0.1)1 (0.3)25 (0.5)
C + UM + MLM4 (2.1)21 (3.4)50 (2.1)12 (0.8)1 (0.3)88 (1.7)
C + UM + MLM + A83 (43.2)394 (64.6)1205 (64.6)577 (37.7)43 (12.0)6 (6.8)6 (9.0)1 (50.0)2315 (44.5)
C + UM + A6 (3.1)10 (1.6)22 (0.9)10 (0.7)1 (0.3)49 (0.9)
C + MLM1 (0.5)1 (0.2)2 (0.0)
C + MLM + A1 (0.5)3 (0.5)15 (0.4)6 (0.4)3 (0.8)1 (1.1)29 (0.6)
C + A4 (2.1)1 (0.2)1 (0.0)2 (0.1)8 (0.2)
UM2 (1.0)4 (0.7)11 (0.5)2 (0.1)19 (0.4)
UM + MLM3 (1.6)8 (1.3)40 (1.7)27 (1.8)4 (1.1)82 (1.6)
UM + MLM + A5 (2.6)125 (20.5)847 (35.9)675 (44.1)115 (32.2)24 (27.3)3 (4.5)1 (50.0)1795 (34.5)
UM + A5 (0.8)14 (0.6)9 (0.6)3 (0.8)1 (1.1)32 (0.6)
MLM2 (0.3)11 (0.5)15 (1.0)3 (0.8)2 (2.3)1 (1.5)34 (0.7)
MLM + A4 (0.7)48 (2.0)130 (8.5)139 (38.9)39 (44.3)33 (49.3)399 (7.7)
A1 (0.5)5 (0.8)14 (0.6)24 (1.6)40 (11.2)14 (15.9)20 (29.9)118 (2.3)
Total19261023591529357886725204

C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes

Table 19

Reconstruction route

RouteCases (%)
None47 (0.9)
Subcutaneous345 (6.6)
Retrosternal2315 (44.5)
Posterior mediastinal1920 (36.9)
Intrathoracic465 (8.9)
Cervical65 (1.2)
Others41 (0.8)
Unknown6 (0.1)
Total5204
Table 20

Organs used for reconstruction

OrgansCases (%)
None85 (1.6)
Whole stomach105 (2.0)
Gastric tube4425 (84.3)
Jejunum272 (5.2)
Free jejunum119 (2.3)
Colon197 (3.8)
Free colon10 (0.2)
Others36 (0.7)
Total organs5249
Total cases5119
Table 21

Histological classification

Histological classificationCases (%)
Squamous cell carcinoma4324 (83.1)
 Squamous cell carcinoma751 (14.4)
 Well differentiated764 (14.7)
 Moderately differentiated2172 (41.7)
 Poorly differentiated637 (12.2)
Adenocarcinoma347 (6.7)
Barrett's carcinoma113 (2.2)
Adenosquamous carcinoma29 (0.6)
Mucoepidermoid carcinoma6 (0.1)
Basaloid carcinoma82 (1.6)
Neuroendocrine tumor2 (0.0)
Neuroendocrine carcinoma25 (0.5)
Undifferentiated carcinoma5 (0.1)
Malignant melanoma19 (0.4)
Carcinosarcoma37 (0.7)
GIST7 (0.1)
Adenoid cystic carcinoma1 (0.0)
Sarcoma2 (0.0)
Other carcinomas8 (0.2)
Other tumors54 (1.0)
Unknown143 (2.7)
Total5204
Table 22

Pathological depth of tumor invasion, pT (JES 10th)

Pathological depth of tumor invasionCases (%)
pTx42 (0.8)
pT0227 (4.4)
pT1a645 (12.4)
pT1b1475 (28.3)
pT2590 (11.3)
pT31962 (37.7)
pT4a141 (2.7)
pT4b122 (2.3)
Total5204
Table 23

Pathological grading of lymph-node metastasis, pN (JES 10th)

Lymph-node metastasisCases (%)
pN02568 (49.3)
pN1962 (18.5)
pN2966 (18.6)
pN3371 (7.1)
pN4321 (6.2)
Unknown16 (0.3)
Total5204
Table 24

Pathological grading of lymph-node metastasis, pN (UICC TNM 7th)

Lymph-node metastasisCases (%)
pN02611 (50.2)
pN1 (1–2)1397 (26.8)
pN2 (3–6)787 (15.1)
pN3 (7-)373 (7.2)
Unknown36 (0.7)
Total5204
Table 25

Pathological findings of distant organ metastasis, pM (JES 10th)

Distant metastasis (M)Cases (%)
MX110 (2.1)
M04998 (96.0)
M196 (1.8)
Total5204
Table 26

Residual tumor

Residual tumor (R)Cases (%)
RX95 (1.8)
R04663 (89.6)
R1257 (4.9)
R2189 (3.6)
Total5204
Table 27

Cause of death

Cause of deathCases (%)
Death due to recurrence1806 (62.0)
Death due to other cancer231 (7.9)
Death due to other disease (with recurrence)65 (2.2)
Death due to other disease (without recurrence)402 (13.8)
Death due to other disease (recurrence unknown)12 (0.4)
Operative death*39 (1.3)
Postoperative hospital death**65 (2.2)
Unknown291 (10.0)
Total of death cases2911

Operative mortality rate: 0.75%

*Operative death means death within 30 days after operation in or out of hospital

**Hospital death is defined as death during the same hospitalization, regardless of department at time of death. Hospital mortality rate: 2.0%

Fig. 7

Survival of patients who underwent esophagectomy

Fig. 8

Survival of patients who underwent esophagectomy according to the clinical stage (JES 10th)

Fig. 9

Survival of patients who underwent esophagectomy according to the clinical stage (UICC TNM 7th)

Fig. 10

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)

Fig. 11

Survival of patients who underwent esophagectomy according to lymph-node metastasis (JES 10th)

Fig. 12

Survival of patients who underwent esophagectomy according to lymph-node metastasis (UICC TNM 7th)

Fig. 13

Survival of patients who underwent esophagectomy according to the pathological stage (JES 10th)

Fig. 14

Survival of patients who underwent esophagectomy according to the pathological stage (UICC TNM 7th)

Fig. 15

Survival of patients

Cause of death Operative mortality rate: 0.75% *Operative death means death within 30 days after operation in or out of hospital **Hospital death is defined as death during the same hospitalization, regardless of department at time of death. Hospital mortality rate: 2.0%
Institutions
Ageo Central General Hospital
Aichi Cancer Center
Aichi Medical University Hospital
Aizawa Hospital
Akita University Hospital
Arao Municipal Hospital
Asahi Rousai Hospital
Asahikawa Medical University Hospital
Cancer Institute Hospital of JFCR
Chiba Cancer Center
Chiba University Hospital
Chiba-ken Saiseikai Narashino Hospital
Dokkyo Medical University Hospital
Dokkyo Medical University Saitama Medical Center
Edogawa Hospital
Ehime Prefectural Central Hospital
Eijyu General Hospital
Fuchu Hospital
Fuji City General Hospital
Fujinomiya City General Hospital
Fujioka General Hospital
Fujisaki Hospital
Fujita Health University Hospital
Fukaya Red Cross Hospital
Fukui University Hospital
Fukui-ken Saiseikai Hospital
Fukuoka City Hospital
Fukuoka Shin Mizumaki Hospital
Fukuoka University Chikushi Hospital
Fukuoka University Hospital
Fukushima Medical University Hospital
Fukuyama City Hospital
Fussa Hospital
Gifu Prefectural General Center
Gifu University Hospital
Gunma Prefectural Cancer Center
Gunma Saiseikai Maebashi Hospital
Gunma University Hospital
Hachinohe City Hospital
Hagi City Hospital
Hakodate City Hospital
Hakodate Goryokaku Hospital
Hakodate National Hospital
Hamamatsu University Hospital
Hannan Chuo Hospital
Hasuda Hospital
Heartlife Hospital
Higashiosaka City Medical Center
Hiraka General Hospital
Hiratsuka City Hospital
Hirosaki University Hospital
Hiroshima City Asa Hospital
Hiroshima City Hospital
Hiroshima Prefectural Hospital
Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital
Hiroshima University Hospital
Hitachi General Hospital
Hofu Institute of Gastroenterology
Hokkaido University Hospital
Hospital of the University of Occupational and Environmental Health, Japan
Hyogo Cancer Center
Hyogo Prefectural Amagasaki General Medical Center
Hyogo Prefectural Nishinomiya Hospital
Ibaraki Prefectural Central Hospital
Iizuka Hospital
Ikeda City Hospital
Imari Arita Kyoritsu Hospital
International University of Health and Welfare Atami Hospital
International University of Health and Welfare Hospital
International University of Health and Welfare Mita Hospital
Isehara Kyodo Hospital
Iseikai Hospital
Ishikawa Prefectural Central Hospital
Itami City Hospital
Iwata City Hospital
Iwate Medical University Hospital
Iwate Prefectural Central Hospital
Iwate Prefectural Chubu Hospital
JA Hiroshima General Hospital
JA Kouseiren Enshu Hospital
JA Onomichi General Hospital
Japanese Red Cross Ashikaga Hospital
Japanese Red Cross Fukuoka Hospital
Japanese Red Cross Ishinomaki Hospital
Japanese Red Cross Kitami Hospital
Japanese Red Cross Kyoto Daiichi Hospital
Japanese Red Cross Maebashi Hospital
Japanese Red Cross Medical Center
Japanese Red Cross Musashino Hospital
Japanese Red Cross Nagoya Daiichi Hospital
Japanese Red Cross Nagoya Daini Hospital
Japanese Red Cross Saitama Hospital
Japanese Red Cross Tottori Hospital
Japanese Red Cross Wakayama Medical Center
Japanese Red Cross Yamaguchi Hospital
JCHO Gunma Chuo Hospital
JCHO Kyushu Hospital
JCHO Osaka Hospital
JCHO Saitama Medical Center
Jichi Medical University Hospital
Jichi Medical University Saitama Medical Center
Juntendo University Hospital
Juntendo University Nerima Hospital
Juntendo University Shizuoka Hospital
Juntendo University Urayasu Hospital
Junwakai Memorial Hospital
Kagawa Prefectural Central Hospital
Kagawa Rosai Hospital
Kagawa University Hospital
Kagoshima City Hospital
Kagoshima University Hospital
Kakogawa Central City Hospital
Kanagawa Cancer Center
Kanagawa Prefectural Ashigarakami Hospital
Kanazawa Medical University Hospital
Kanazawa University Hospital
Kansai Denryoku Hospital
Kansai Medical University Hospital
Kansai Medical University Medical Center
Kansai Rosai Hospital
Kashiwa Kousei General Hospital
Kasugai Municipal Hospital
Kawakita General Hospital
Kawasaki Medical School Hospital
Kawasaki Medical School Kawasaki Hospital
Kawasaki Municipal Hospital
Kawasaki Municipal Ida Hospital
Kawasaki Saiwai Hospital
Keio University Hospital
Keiyukai Sapporo Hospital
Kindai University Hospital
Kindai University Nara Hospital
Kinki Central Hospital
Kiryu Kousei General Hospital
Kishiwada City Hospital
Kitaakita Municipal Hospital
Kitaharima Medical Center
Kitakyushu Municipal Medical Center
Kitano Hospital
Kitasato University Hospital
Kobe City Medical Center General Hospital
Kobe University Hospital
Kochi Health Science Center
Kochi University Hospital
Kokura Memorial Hospital
Kosei Hospital
Kouseiren Takaoka Hospital
Kumagai General Hospital
Kumamoto University Hospital
Kumamoto Regional Medical Center
Kurashiki Central Hospital
Kurume University Hospital
Kyonan Medical Center Fujikawa Hospital
Kyorin University Hospital
Kyoto University Hospital
Kyoto-Katsura Hospital
Kyushu Central Hospital
Kyushu University Hospital
Machida Municipal Hospital
Matsudo City General Hospital
Matsushita Memorial Hospital
Matsuyama Red Cross Hospital
Mie University Hospital
Minamiosaka Hospital
Minoh City Hospital
Mito Red Cross Hospital
Mitsui Memorial Hospital
Miyazaki University Hospital
Moriguchi Keijinkai Hospital
Nagahama City Hospital
Nagahama Red Cross Hospital
Nagano Municipal Hospital
Nagaoka Chuo General Hospital
Nagasaki University Hospital
Nagoya City University Hospital
Nagoya City West Medical Center
Nagoya Tokushukai General Hospital
Nagoya University Hospital
Nanpuh Hospital
Nara City Hospital
Nara Medical University Hospital
Nasu Red Cross Hospital
National Cancer Center Hospital
National Cancer Center Hospital East
National Center for Global Health and Medicine
National Defence Medical College Hospital
Nerima Hikarigaoka Hospital
New Tokyo Hospital
NHO Beppu Medical Center
NHO Chiba Medical Center
NHO Iwakuni Clinical Center
NHO Kure Medical Center
NHO Kyoto Medical Center
NHO Kyushu Cancer Center
NHO Kyushu Medical Center
NHO Matsumoto Medical Center
NHO Mito Medical Center
NHO Miyakonojo Medical Center
NHO Nagasaki Medical Center
NHO Nagoya Medical Center
NHO Okayama Medical Center
NHO Osaka Medical Center
NHO Saga Hospital
NHO Saitama Hospital
NHO Sendai Medical Center
NHO Shikoku Cancer Center
NHO Takasaki General Medical Center
NHO Tokyo Medical Center
NHO Yokohama Medical Center
Nihonkai General Hospital
Niigata Cancer Center Hospital
Niigata City General Hospital
Niigata Prefectural Shibata Hospital
Niigata University Medical & Dental Hospital
Nikko Memorial Hospital
Nippon Medical School Chiba Hokusou Hospital
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
Nippon Medical School Tama Nagayama Hospital
Nishi Kobe Medical Center
Northern Okinawa Medical Center
NTT Medical Center Tokyo
Numazu City Hospital
Obihiro Kousei Hospital
Ogaki Municipal Hospital
Ogikubo Hospital
Ogori Daiichi General Hospital
Ohta Hospital
Ohta Nishinouchi Hospital
Oita Prefectural Hospital
Oita Red Cross Hospital
Oita University Hospital
Okayama City Hospital
Okayama Red Cross General Hospital
Okayama Saiseikai General Hospital
Okayama University Hospital
Okitama Public General Hospital
Onomichi Municipal Hospital
Osaka City General Hospital
Osaka City University Hospital
Osaka General Medical Center
Osaka International Cancer Institute
Osaka Medical College Hospital
Osaka Police Hospital
Osaka Red Cross Hospital
Osaka University Hospital
Osaki City Hospital
Otemae Hospital
Otsu City Hospital
Rinku General Medical Center
Saga Prefectural Hospital Koseikan
Saga University Hospital
Saiseikai Fukuoka General Hospital
Saiseikai Karatsu Hospital
Saiseikai Kyoto Hospital
Saiseikai Noe Hospital
Saiseikai Utsunomiya Hospital
Saiseikai Yamaguchi General Hospital
Saiseikai Yokohama Tobu Hospital
Saitama Medical University International Medical Center
Saitama Medical University Saitama Medical Center
Sakai City Medical Center
Saku Central Hospital
Sapporo Medical University Hospital
Seikei-kai Chiba Medical Center
Seirei Hamamatsu General Hospital
Sendai City Hospital
Sendai Kosei Hospital
Shiga General Hospital
Shiga University of Medical Science Hospital
Shimane University Hospital
Shin Takeo Hospital
Shinko Hospital
Shinshu University Hospital
Shizuoka Cancer Center
Shizuoka City Shizuoka Hospital
Shizuoka General Hospital
Showa University Hospital
Southern Tohoku General Hospital
St. Luke's International Hospital
St. Marianna University School of Medicine Hospital
St. Mary's Hospital
Steel Memorial Yawata Hospital
Suita Municipal Hospital
Tachikawa Hospital
Tagawa Municipal Hospital
Takatsuki Red Cross Hospital
Teikyo University Chiba Medical Center
Teikyo University Hospital
Teikyo University Hospital Mizonokuchi
Teine Keijinkai Hospital
Tenri Hospital
The Hospital of Hyogo College of Medicine
The Jikei University Daisan Hospital
The Jikei University Hospital
Tochigi Cancer Center
Toda Central General Hospital
Toho University Ohashi Medical Center
Toho University Omori Medical Center
Toho University Sakura Medical Center
Tohoku University Hospital
Tokai University Hachioji Hospital
Tokai University Hospital
Tokai University Tokyo Hospital
Tokushima Red Cross Hospital
Tokushima University Hospital
Tokyo Dental College Ichikawa General Hospital
Tokyo Medical and Dental University Hospital
Tokyo Medical University Hachioji Medical Center
Tokyo Medical University Hospital
Tokyo Medical University Ibaraki Medical Center
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Tokyo Metropolitan Tama Medical Center
Tokyo University Hospital
Tokyo Women's Medical University Hospital
Tokyo Women's Medical University Medical Center East
Tokyo Women's Medical University Yachiyo Medical Center
Tonan Hospital
Toshima Hospital
Tottori Prefectural Central Hospital
Tottori University Hospital
Toyama Prefectural Central Hospital
Toyama University Hospital
Toyonaka Municipal Hospital
Toyota Kosei Hospital
Toyota Memorial Hospital
Tsuchiura Kyodo Hospital
Tsukuba University Hospital
Tsuruoka Municipal Shonal Hospital
University Hospital, Kyoto Prefectural University of Medicine
University of the Ryukyus Hospital
Wakayama Medical University Hospital
Yamagata Prefectural Central Hospital
Yamagata University Hospital
Yamaguchi University Hospital
Yamanashi Prefectural Central Hospital
Yamanashi University Hospital
Yao Municipal Hospital
Yokkaichi Hospital
Yokohama City Municipal Hospital
Yokohama City University Hospital
Yokohama City University Medical Center
Yonezawa City Hospital
Yuai Memorial Hospital
Follow-up period (months)
Median (min.–max.)55.29 (0.07–78.78)
  1 in total

1.  Japanese Classification of Esophageal Cancer, 11th Edition: part I.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

  1 in total
  5 in total

1.  Neutrophil-Lymphocyte Ratio Is Associated With Occurrence of Febrile Neutropenia in Patients Treated With 5-Fluorouracil and Cisplatin.

Authors:  Satomi Kumazawa; Tomohiro Mizuno; Naoyuki Muramatsu; Masakazu Hatano; Takenao Koseki; Hiroshi Matsuoka; Koichi Suda; Ichiro Uyama; Shigeki Yamada
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Essential risk factors for operative mortality in elderly esophageal cancer patients registered in the National Clinical Database of Japan.

Authors:  Kentaro Murakami; Yasunori Akutsu; Hiroaki Miyata; Yasushi Toh; Takeshi Toyozumi; Yoshihiro Kakeji; Yasuyuki Seto; Hisahiro Matsubara
Journal:  Esophagus       Date:  2022-09-20       Impact factor: 3.671

Review 3.  The potential for reducing alcohol consumption to prevent esophageal cancer morbidity in Asian heavy drinkers: a systematic review and meta-analysis.

Authors:  Yuto Kubo; Yuko Kitagawa; Tatsuya Miyazaki; Makoto Sohda; Taiki Yamaji; Makoto Sakai; Hiroshi Saeki; Kenji Nemoto; Tsuneo Oyama; Manabu Muto; Hiroya Takeuchi; Yasushi Toh; Hisahiro Matsubara; Masayuki Mano; Koji Kono; Ken Kato; Masahiro Yoshida; Hirofumi Kawakubo; Eisuke Booka; Tomoki Yamatsuji; Hiroyuki Kato; Yoshinori Ito; Hitoshi Ishikawa; Ryu Ishihara; Takahiro Tsushima; Hiroshi Kawachi; Takashi Oyama; Takashi Kojima; Shiko Kuribayashi; Tomoki Makino; Satoru Matsuda; Yuichiro Doki
Journal:  Esophagus       Date:  2021-10-24       Impact factor: 4.230

Review 4.  Endoscopic Diagnosis and Treatment of Superficial Esophageal Squamous Cell Cancer: Present Status and Future Perspectives.

Authors:  Ryu Ishihara
Journal:  Curr Oncol       Date:  2022-01-26       Impact factor: 3.677

Review 5.  Management of elderly patients with esophageal squamous cell cancer.

Authors:  Yasuo Hamamoto; Kentaro Murakami; Ken Kato; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2022-08-05       Impact factor: 2.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.